Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Taylor Morrisette; Kyle C Molina; Beatriz Da Silva; Scott W Mueller; Laura Damioli; Martin Krsak; Matthew A Miller; Douglas N Fish

doi:10.1093/ofid/ofac028

Real-World Use of Tedizolid Phosphate for 28 Days or More: A Case Series Describing Tolerability and Clinical Success

Open Forum Infect Dis. 2022 May 23;9(6):ofac028. doi: 10.1093/ofid/ofac028. eCollection 2022 Jun.

Authors

Taylor Morrisette¹, Kyle C Molina², Beatriz Da Silva¹, Scott W Mueller¹, Laura Damioli³, Martin Krsak³, Matthew A Miller², Douglas N Fish¹

Affiliations

¹ Department of Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
² Department of Pharmacy-Infectious Diseases, University of Colorado Hospital, Aurora, Colorado, USA.
³ Department of Medicine, University of Colorado Hospital, Aurora, Colorado, USA.

Abstract

Tedizolid has activity against Gram-positive pathogens as well as Mycobacterium spp and Nocardia spp. Real-world evidence supporting long-term tolerability and clinical success of tedizolid is lacking. Prolonged tedizolid therapy (median, 188 days; interquartile range, 62-493 days) appeared to be well tolerated in 37 patients (8.1% experienced adverse effect leading to discontinuation). Clinical success was 81.3% in those evaluated.

Keywords: Gram-positive infections; long-term tolerability; tedizolid; thrombocytopenia.